Active STAT5 recruits BRD2 to assist in the assembly of the pre-initiation complex and regulate MYC transcription, suggesting that bromodomain inhibitors, such as JQ1 derivatives, can be effective in CML [193,194]. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.